» Articles » PMID: 18590725

Berberine Inhibits Platelet-derived Growth Factor-induced Growth and Migration Partly Through an AMPK-dependent Pathway in Vascular Smooth Muscle Cells

Overview
Journal Eur J Pharmacol
Specialty Pharmacology
Date 2008 Jul 2
PMID 18590725
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Platelet-derived growth factor (PDGF) is released from vascular smooth muscle cells (VSMCs), endothelial cells, or macrophages after percutaneous coronary intervention and is related with neointimal proliferation and restenosis. Berberine is a well-known component of the Chinese herb medicine Huanglian (Coptis chinensis), and is capable of inhibiting growth and endogenous PDGF synthesis in VSMCs after in vitro mechanical injury. We analyzed the effects of berberine on VSMC growth, migration, and signaling events after exogenous PDGF stimulation in vitro in order to mimic a post-angioplasty PDGF shedding condition. Pretreatment of VSMCs with berberine inhibited PDGF-induced proliferation. Berberine significantly suppressed PDGF-stimulated Cyclin D1/D3 and Cyclin-dependent kinase (Cdk) gene expression. Moreover, berberine increased the activity of AMP-activated protein kinase (AMPK), which led to phosphorylation activation of p53 and increased protein levels of the Cdk inhibitor p21(Cip1). Compound C, an AMPK inhibitor, partly but significantly attenuated berberine-elicited growth inhibition. In addition, stimulation of VSMCs with PDGF led to a transient increase in GTP-bound, active form of Ras, Cdc42 and Rac1, as well as VSMC migration. However, pretreatment with berberine significantly inhibited PDGF-induced Ras, Cdc42 and Rac1 activation and cell migration. Co-treatment with farnesyl pyrophosphate and geranylgeranyl pyrophosphate drastically reversed berberine-mediated anti-proliferative and migratory effects in VSMCs. Based on these findings, we conclude that berberine inhibited PDGF-induced VSMC growth via activation of AMPK/p53/p21(Cip1) signaling while inactivating Ras/Rac1/Cyclin D/Cdks and suppressing PDGF-stimulated migration via inhibition of Rac1 and Cdc42. These observations offer a molecular explanation for the anti-proliferative and anti-migratory properties of berberine.

Citing Articles

Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends.

Behl T, Singh S, Sharma N, Zahoor I, Albarrati A, Albratty M Molecules. 2022; 27(12).

PMID: 35744831 PMC: 9229453. DOI: 10.3390/molecules27123705.


Natural AMPK Activators in Cardiovascular Disease Prevention.

Heidary Moghaddam R, Samimi Z, Asgary S, Mohammadi P, Hozeifi S, Hoseinzadeh-Chahkandak F Front Pharmacol. 2022; 12:738420.

PMID: 35046800 PMC: 8762275. DOI: 10.3389/fphar.2021.738420.


Effects of Berberine on Atherosclerosis.

Rui R, Yang H, Liu Y, Zhou Y, Xu X, Li C Front Pharmacol. 2021; 12:764175.

PMID: 34899318 PMC: 8661030. DOI: 10.3389/fphar.2021.764175.


Atheroprotective Effects and Molecular Mechanism of Berberine.

Xing L, Zhou X, Li A, Li H, He C, Qin W Front Mol Biosci. 2021; 8:762673.

PMID: 34869592 PMC: 8636941. DOI: 10.3389/fmolb.2021.762673.


A Novel Promising Frontier for Human Health: The Beneficial Effects of Nutraceuticals in Cardiovascular Diseases.

Carrizzo A, Izzo C, Forte M, Sommella E, Di Pietro P, Venturini E Int J Mol Sci. 2020; 21(22).

PMID: 33218062 PMC: 7698807. DOI: 10.3390/ijms21228706.